"Old Qi, sit down." Shen Qi poured a glass of water for Director Qi.

"Yes, your chemical project C01B, which is a benzoazepine compound mentioned in the paper published on JACS, has a pharmaceutical company that wants to buy your patent." Director Qi is indeed the center. The God of Wealth, he said again: "The pharmaceutical company may not dare to directly look for a big figure like you, so I found me."

"No problem, we can transfer the patent of C01B, who is the buyer?" Shen Qi asked.

Director Qi said: "The buyer is Lushan Pharmaceutical, a subsidiary of Pfizer in China, a US-owned company."

Shen Qi said "Oh": "Pfizer's subsidiary, it's interesting."

Director Qi, who is proficient in law and business operations, said: "I have generally learned about some things. Your C01B is said to be similar to the smoking cessation drug that Pfizer launched in 1997. The administrative protection of the drug in my country has expired. That is to say, the patent for this smoking cessation drug has expired. When I was studying in the United States, I studied Pfizer's operation case. In the past 20 years, Pfizer has invested a lot of manpower, material and financial resources in acquisitions."

The status quo of Chinese chemical drugs is that once the patents of patented drugs on the market expire, a large number of generic drugs will emerge. As a result, generic drugs account for more than 90% of the Chinese chemical drug market.

There are advantages and disadvantages. Generic drugs that are almost as effective as the original drugs are cheaper and ordinary people can afford them.

However, from the long-term development of China's pharmaceutical industry, the disadvantages outweigh the advantages.

Most of China's pharmaceutical companies blindly imitate, resulting in very weak core research and development capabilities, and almost lost their innovation capabilities.

The pharmaceutical industry is a technology-led industry. After all, pharmaceutical companies without technological innovation capabilities will not be able to grow bigger and stronger, or even survive.

There are too many generic drugs of the same type, and pharmaceutical companies have begun to fight price wars.

Many small and medium-sized pharmaceutical companies in China specialize in the production of generic drugs. In the fierce competition and even chaotic price wars, most small and medium-sized pharmaceutical companies lose money all the year round, go bankrupt, or are acquired by large pharmaceutical groups.

Another big market for generic drugs is India. There is a pharmaceutical company in India, Aurobindo, that specializes in imitating Pfizer’s patented drugs. The quality of the imitated drugs is quite high, so high that even the FDA has approved it.

This Indian pharmaceutical company has imitated more than 100 kinds of Pfizer patented drugs, of which 39 generic drugs have obtained the right to operate in the US market.

The United States promotes global trade, fair competition, and opposes monopoly. At least the US government is fairly fair to Indian companies.

The drug patent has expired, and people have the right to imitate it, and Pfizer cannot fight a lawsuit.

In the case studied by Director Qi, Pfizer changed its operating model. Since it was unable to crack down on the copycat factory, Pfizer acquired the Indian pharmaceutical company Aurobindo, which has been committed to imitating them for a lifetime.

At the same time, Greenstone Pharmaceuticals, a wholly-owned subsidiary of Pfizer, purchased a large number of generic drugs after patent expiration worldwide.

The wealthy pharmaceutical giant Pfizer's current operating model is to maintain its core competitiveness in independent research and development of new drugs, and to simultaneously acquire generic drug companies and generic drugs.

The business that Pfizer established in China, Green Mountain Pharmaceuticals, is similar to that of the Greenstone company they established in the United States, with only three words: buy, buy, buy.

Shen Qi said: "So in Pfizer's view, our C01B imitates their precepts?"

Director Qi explained: “The patent bill for medicines is very complicated and difficult to describe in one word. Simply put, the same medicine can also apply for different patents due to different preparation methods. This is a patent on technology.”

During this time, Shen Qi has also learned the rules of the game in the pharmaceutical industry. There is a senior person in his family who is his doctor's mother.

Since the middle of the 20th century, the research and development of chemical drugs has made great progress thanks to the development of chemical science. Some new compounds were quickly identified in the laboratory and used in clinical research.

After decades of development, today's chemical drug research and development is becoming more and more complex and long. The subjects involved are not only chemistry, but also biology, medicine, information science (computer-assisted), materials science and other knowledge.

At present, it takes an average of 12 years for a new drug to go from initial laboratory research to market sales.

According to statistics from the World Health Organization, only 5 of the 5000 compounds in pre-clinical trials can enter the follow-up clinical trials.

Only one of these compounds can be finally approved and marketed.

The research and development cycle of a complete set of new compounds is more than 10 years, and the average cost is several billion US dollars. It is normal for international pharmaceutical giants or large CROs to have more than 100 professionals in their research teams and testing teams for a single compound. The process is extremely cumbersome and complicated.

Shen Qi can only do the laboratory synthesis of samples and the stage of animal experiments. His center temporarily does not have the conditions to complete the full set of drug research and development, testing, and improvement: "I decided to sell the C01B patent."

Director Qi reminded: "Americans will not bid too high."

Shen Qi nodded and said: "Understand, my C01B has not done any experiments, even animal experiments. Since Lushan Pharmaceutical Co., Ltd. dares to buy, then I dare to sell."

Compounds undergoing pre-clinical testing can enter clinical stage I, that is, to test whether the compound has toxicity or other dangerous side effects on normal healthy people. This promotion rate is only one in a thousand.

After clinical phase I, there are II~IV, and the uncertainty is too high.

The C01B synthesized by Shen Qi and Lao Yan Wai Da is not to mention clinical, even animal experiments have not been done.

Whether C01B has actual value or not will be determined after many years.

At this stage, some people dare to buy the laboratory compound C01B, which requires a strong predictive power and also has a gambling component.

Drug development is an industry full of drama.

The new drug R&D team of Ragan Company in the United States successfully synthesized a new compound sevoflurane in an experiment in 1968. They observed that the sevoflurane decomposition product had certain nephrotoxicity in a high temperature test at 210 degrees Celsius.

Therefore, American researchers believed that sevoflurane had no future, and sold its patent to Japan's Maruishi company at a very low price.

Maruishi Company is stealing joy, they are like treasures.

After optimization and improvement, Maruishi launched an improved version of sevoflurane in 1993, which was first launched in Japan under the trade name Ultane.

In nearly 2 million clinical observations, sevoflurane showed excellent efficacy and safety, and it was subsequently marketed in dozens of countries including China, the United States, and South Korea.

The Chinese trade name of sevoflurane is Kateli, which is an inhaled general anesthetic. Many hospitals in China use Kateli when operating on patients.

Compounds that have no future in the eyes of American researchers have become treasures in the hands of Japanese pharmacologists. This is the drama of the drug development industry.

Of course, the cycle of turning waste into treasure is quite long. It took Maruishi company 25 years to make sevoflurane an excellent anesthetic recognized by the medical community.

Not to mention 25 years. Shen Qi didn’t want to wait for 5 years. His purpose in entering the chemical industry was not to develop smoking cessation drugs. C01B was just a windfall: "Then I’ll ask Director Qi. I mean C01B can be sold at a patent transfer price. Director Qi will follow the rules and talk to the other party."

In response to the old saying, mathematical physics is a prairie fire is a light that points the way, chemical biology is a crematorium is a pit for burying science students.

Shen Qi lit the fire and lit the lamp.

Now Shen Qi is in the pit, this is the fate of science students.

Playing biochemistry is really a complicated project, and Shen Qi still plays mathematics, physics and politics most smoothly.

Because of Director Qi's temporary visit, Shen Qi only wrote an extra part on condensed matter physics before leaving get off work at 5 o'clock.

"I will work overtime today and go home before 10 o'clock." Shen Qi sent a message to Ou Ye, and he wanted to work hard to get the other two physics extras.

There are a total of four chapters in mathematics and physics, and Shen Qi predicts that he can save enough points to advance to 15 levels in mathematics.

Ou Ye replied: "Go home for dinner first, and work overtime after eating."

The Villa of Academician Shen is very close to Yanda University, only ten minutes' walk away.

The big wife in heaven and earth is the biggest, and the wife orders to go home to eat, then he must go home to eat.

Shen Qi went home for dinner, after the meal, teased the baby, and added a ghost class, not wanting to work overtime.

The next day, Shen Qi finished all the extra articles, sent them to relevant mathematics and physics journals, and then reviewed the documents that needed his confirmation.

The leader of a scientific research institution or scientific research team is called the boss ~lightnovelpub.net~ because the bosses are busy with business and there are a lot of documents that need to be handled by the boss.

Especially if he is a boss at the level of enthusiasm, his signature may involve tens of millions or even billions of scientific research funds.

Researchers with the title of associate professor or above in the center are all eligible to apply for research projects individually.

After receiving the training of the principal of the party school, Shen Qi was very cautious about large-amount scientific research funding applications.

It didn't matter for projects under 1 million, Shen Qi approved it easily.

Shen Qi must strictly control theoretical research projects with more than 1 million yuan and applied projects with more than 10 million yuan.

Associate Professor Xiao Junlong submitted an application for a mathematics project, the application for a funding of 986,327 yuan, there are all parts and the list is clear.

"Kavalve, right? Lao Xiao, you have studied me thoroughly." Shen Qi's hand holding the pen hasn't signed for a long time, and all of his people have become sophisticated.